ANI Pharmaceuticals ANIP Accrued royalties
Accrued royalties at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept anip:IncreaseDecreaseInRoyaltyPayable.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's accrued royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's accrued royalties?
- ANI Pharmaceuticals (ANIP) reported accrued royalties of -$14.66M in Q1 2026.
- How has ANI Pharmaceuticals's accrued royalties changed year-over-year?
- ANI Pharmaceuticals's accrued royalties decreased by 1448.2% year-over-year, from $1.09M to -$14.66M.
- What does accrued royalties mean?
- Tracks the net change in liabilities owed to third parties for the use of intellectual property or licensed technologies. This metric highlights the timing differences between the recognition of royalty expenses and the actual cash settlement with licensors. It provides insight into the company's ongoing obligations related to its product portfolio.